Portola Pharmaceuticals is a biopharmaceutical company that discovers and develops innovative therapeutics based on targets with established proof of concept that are designed to provide significant advances over current treatments for cardiovascular and autoimmune/inflammatory diseases. Portola scientists have successfully collaborated for over 15 years on the discovery and development of novel small molecule agents targeting platelets, coagulation pathways and protein kinases. Learn More

News & Events

  • J.P.Morgan Presentation Focused on Three Transformational Programs for 2012 PDF
  • Portola Pharmaceuticals Announces Completion of $89 Million Financing PDF

Portola Profiles

Portola Profiles
Meet a few of the people that help define Portola innovation. More